![Presidential_Besse](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/21.10.2023/presidential_besse/18325706-1-eng-GB/presidential_besse_i770.jpg)
Adding amivantamab to chemotherapy prolongs PFS in untreated EGFR exon 20 insertion-mutated advanced NSCLC
The bispecific EGFR/MET-directed monoclonal antibody looks set to become the standard of care in this setting, but toxicity has to be managed carefully